4602-73-7

Usage

Uses

Used in Pharmaceutical Industry:
7-Hydroxy-6-methoxy-3,4-dihydroisoquinoline is used as a reagent for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a key component in the development of new drugs with potential therapeutic benefits.
Used in Neurology:
7-Hydroxy-6-methoxy-3,4-dihydroisoquinoline is used as a dual dopamine D1 receptor agonist/D2 receptor antagonist. This dual activity makes it a promising candidate for the treatment of neurological disorders, particularly schizophrenia. Its ability to modulate dopamine receptor activity can help in managing the symptoms and improving the quality of life for patients suffering from this mental health condition.
Used in Medicinal Chemistry Research:
7-Hydroxy-6-methoxy-3,4-dihydroisoquinoline is used in the study of structure-activity relationships (SAR) of tetrahydroisoquinolines. Understanding the SAR of 7-Hydroxy-6-methoxy-3,4-dihydroisoquinoline can provide valuable insights into the design and development of more effective drugs for the treatment of schizophrenia and other related disorders.

InChI:InChI=1/C9H7NO/c11-9-2-1-7-3-4-10-6-8(7)5-9/h1-6,11H

Upstream product

• 3382-18-1 6,7-dimethoxy-3,4-dihydro-isoquinoline 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 282721-32-8 N-[2-(4-hydroxy-3-methoxyphenyl)ethyl]formamide 
• 55803-41-3 N-formyl-2-[3-methoxy-4-(benzyloxy)phenyl]ethylamine 

Downstream Products

• 111599-06-5 (7-Hydroxy-6-methoxy-1,2,3,4-tetrahydro-isoquinolin-1-yl)-acetic acid 
• 111599-04-3 (7-Hydroxy-6-methoxy-1,2,3,4-tetrahydro-isoquinolin-1-yl)-acetic acid ethyl ester 
• 1426260-82-3 8-(2,4-dimethoxyphenyl)-2-(2-fluorophenethyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol 
• 1426260-61-8 2-(2-fluorophenethyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol 
• 1426260-65-2 8-bromo-2-(2-chlorophenethyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol 
• 1426260-64-1 8-bromo-6-methoxy-2-(4-nitrophenethyl)-1,2,3,4-tetrahydroisoquinolin-7-ol 

Relevant academic research and scientific papers

Peganumine A alkaloid structure simplifier and application thereof

The invention discloses a Peganumine A alkaloid structure simplifier, a stereoisomer or a pharmaceutical salt thereof. The structure is shown in the following general formula: each substituent group is defined in the specification. The simplified structure of the Peganumine A alkaloid provided by the invention has a relatively obvious proliferation inhibition effect on liver cancer HepG2, lung cancer A549 and intestinal cancer HCT116, and the anti-tumor activity of part of compounds is higher than the anti-liver cancer HepG2 activity of Peganumine A reported in literatures.

3-(Phenethylamino)demethyl(oxy)aaptamine as an anti-dormant mycobacterial substance: Isolation, evaluation and total synthesis

3-(Phenethylamino)demethyl(oxy)aaptamine (1) was re-discovered from the marine sponge of Aaptos sp. as an anti-dormant mycobacterial substance through the bioassay-guided separation. Compound 1 showed potent anti-microbial activity against Mycobacterium bovis BCG with a minimum inhibitory concentration of 0.75 μg/mL under both aerobic conditions and hypoxic conditions inducing dormant state. Compound 1 was also effective against pathogenic M. tuberculosis strains including clinical multidrug-resistant strains. Furthermore, the successful total syntheses of 1 and its analog 3-aminodemethyl(oxy)aaptamine (2) afford sufficient quantities for further biological studies.

PHARMACEUTICAL COMPOUNDS

This application describes substituted 1,3,4,6,7,11b-hexahydro-benzo(a)quinolizine compounds, pharmaceutical compositions containing them, processes for making them and their therapeutic methods.

Synthesis of the Marine Alkaloids Aaptamine and Demethyloxyaaptamine and of the Parent Structure Didemethoxyaaptamine

The first synthesis of the novel marine alkaloids aaptamine and demethyloxyaaptamine is described, as well as the first synthesis of the parent heterocycle 1H-benzonaphthyridine (didemethoxyaaptamine).